AKR1C3 as a potential biomarker for sensitivity of T-lineage acute lymphoblastic leukaemia to the pre-prodrug PR-104

多药化疗是治疗儿童ALL最有效的方法，儿童ALL是最常见的儿科恶性肿瘤。尽管在过去的40年里，存活率有了显著的提高，但复发性ALL仍然是儿童死于疾病的最常见原因之一。因此，需要采取创新的战略，使那些对现有治疗反应不佳的儿童受益。这项应用将测试一种针对一种非常侵袭性的儿童白血病亚型的新疗法。

Multiagent chemotherapy is the most effective modality for the treatment of childhood ALL, the most common paediatric malignancy. Despite dramatic improvements in survival over the past 40 years, relapsed ALL remains one of the most common causes of death from disease in children. Therefore, innovative strategies are needed to benefit those children who respond poorly to established therapy. This application will test a novel therapy for a very aggressive subtype of childhood leukaemia.